Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study
Conditions: Alcohol Use Disorder (AUD); Post Traumatic Stress Disorder (PTSD) Interventions: Drug: Placebo; Drug: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg; Drug: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg; Procedure: Ethanol Infusion; Behavioral: PTSD Reactivity Condition; Behavioral: Alcohol Cue R eactivity Sponsors: Pharmacotherapies for Alcohol and Substance Abuse Consortium; United States Department of Defense; Congressionally Directed Medical Research Programs; RTI International; VA Connecticut Healthcare System; BioXcel Therapeutics Inc; Yale University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alcoholism | Politics | Post Traumatic Stress Disorder | Research | Study | Substance Abuse | Substance Abuse Disorders